1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP-DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION

3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. TOPICAL ROUTE OF ADMINISTRATION HOLDS MAJORITY OF THE OVERALL MARKET SHARE
3.2.2. INTERLEUKIN INHIBITOR MARKET IS ANTICIPATED TO GENERATE HIGHEST REVENUE

4. MARKET DETERMINANTS
4.1. MARKET DRIVERS
4.1.1. GROWING PREVALENCE OF FOOD ALLERGIES EXACERBATING ATOPIC DERMATITIS
4.1.2. GROWING FOCUS ON SYSTEMATIC THERAPIES
4.1.3. INCREASING USE OF PHARMACOLOGICAL PRODUCTS IN DEVELOPING COUNTRIES
4.2. MARKET RESTRAINTS
4.2.1. STRINGENT REGULATIONS FOR PRODUCT APPROVAL
4.2.2. GENERIC COMPETITION
4.3. MARKET OPPORTUNITIES
4.3.1. INCREASING M&A LEADING TO MARKET CONSOLIDATION
4.3.2. LAUNCH OF FIRST BIOLOGIC FOR ATOPIC DERMATITIS
4.3.3. GROWING FOCUS ON NOVEL DRUGS
4.4. MARKET CHALLENGES
4.4.1. BLACK BOX WARNING FOR ELIDEL AND PROTOPIC
4.4.2. HIGHLY GENERICIZED MARKET
4.4.3. POOR PATIENT ADHERENCE DUE TO INADEQUATE INFORMATION ON DRUG USAGE

5. MARKET SEGMENTATION
5.1. MARKET BY ROUTE OF ADMINISTRATION (ROA) 2019-2027
5.1.1. TOPICAL
5.1.2. ORAL
5.1.3. INJECTIBLES
5.2. MARKET BY DRUG CLASS 2019-2027
5.2.1. TOPICAL ANTIBIOTICS
5.2.2. TOPICAL ANTIHISTAMINES
5.2.3. TOPICAL CORTICOSTEROIDS
5.2.4. TOPICAL MOISTURIZERS/EMOLLIENTS
5.2.5. TOPICAL CALCINEURIN INHIBITORS
5.2.6. IMMUNOMODULATORS
5.2.7. OFF-LABEL THERAPIES
5.2.8. SYSTEMIC AGENTS
5.2.9. PDE4 INHIBITOR
5.2.10. INTERLEUKIN INHIBITOR

6. KEY ANALYTICS
6.1. PORTER'S FIVE FORCES ANALYSIS
6.1.1. THREAT OF NEW ENTRANTS
6.1.2. THREAT OF SUBSTITUTE
6.1.3. BARGAINING POWER OF SUPPLIERS
6.1.4. BARGAINING POWER OF BUYERS
6.1.5. THREAT OF COMPETITIVE RIVALRY
6.2. OPPORTUNITY MATRIX
6.3. PIPELINE ANALYSIS
6.4. LEGAL, POLICY AND REGULATORY ISSUES

7. GEOGRAPHICAL ANALYSIS
7.1. NORTH AMERICA
7.1.1. THE UNITED STATES
7.1.2. CANADA

8. COMPANY PROFILES
8.1. ALLERGAN PLC
8.1.1. COMPANY OVERVIEW
8.1.2. PRODUCT PORTFOLIO
8.1.3. SWOT ANALYSIS
8.1.4. STRATEGIC INITIATIVES
8.2. AQUA PHARMACEUTICALS (AN ALMIRALL COMPANY)
8.2.1. COMPANY OVERVIEW
8.2.2. PRODUCT PORTFOLIO
8.2.3. SWOT ANALYSIS
8.3. ASTELLAS PHARMA INC.
8.3.1. COMPANY OVERVIEW
8.3.2. PRODUCT PORTFOLIO
8.3.3. SWOT ANALYSIS
8.3.4. STRATEGIC INITIATIVES
8.4. BAYER AG
8.4.1. COMPANY OVERVIEW
8.4.2. PRODUCT PORTFOLIO
8.4.3. SWOT ANALYSIS
8.4.4. STRATEGIC INITIATIVES
8.5. BIOFRONTERA AG
8.5.1. COMPANY OVERVIEW
8.5.2. PRODUCT PORTFOLIO
8.5.3. SWOT ANALYSIS
8.6. BRISTOL-MYERS SQUIBB
8.6.1. COMPANY OVERVIEW
8.6.2. PRODUCT PORTFOLIO
8.6.3. SWOT ANALYSIS
8.7. STIEFEL LABORATORIES, INC
8.7.1. COMPANY OVERVIEW
8.7.2. PRODUCT PORTFOLIO
8.7.3. SWOT ANALYSIS
8.8. ENCORE DERMATOLOGY
8.8.1. COMPANY OVERVIEW
8.8.2. PRODUCT PORTFOLIO
8.8.3. SWOT ANALYSIS
8.8.4. STRATEGIC INITIATIVES
8.9. GALDERMA SA
8.9.1. COMPANY OVERVIEW
8.9.2. PRODUCT PORTFOLIO
8.9.3. SWOT ANALYSIS
8.9.4. STRATEGIC INITIATIVES
8.10. LEO PHARMA
8.10.1. COMPANY OVERVIEW
8.10.2. PRODUCT PORTFOLIO
8.10.3. SWOT ANALYSIS
8.10.4. STRATEGIC INITIATIVES
8.11. MEDA PHARMACEUTICALS (MYLAN N.V.)
8.11.1. COMPANY OVERVIEW
8.11.2. PRODUCT PORTFOLIO
8.11.3. SWOT ANALYSIS
8.11.4. STRATEGIC INITIATIVES
8.12. NOVARTIS AG
8.12.1. COMPANY OVERVIEW
8.12.2. PRODUCT PORTFOLIO
8.12.3. SWOT ANALYSIS
8.12.4. STRATEGIC INITIATIVES
8.13. PFIZER
8.13.1. COMPANY OVERVIEW
8.13.2. PRODUCT PORTFOLIO
8.13.3. SWOT ANALYSIS
8.13.4. STRATEGIC INITIATIVES
8.14. REGENERON PHARMACEUTICALS
8.14.1. COMPANY OVERVIEW
8.14.2. PRODUCT PORTFOLIO
8.14.3. SWOT ANALYSIS
8.14.4. STRATEGIC INITIATIVES
8.15. SANOFI SA
8.15.1. COMPANY OVERVIEW
8.15.2. PRODUCT PORTFOLIO
8.15.3. SWOT ANALYSIS
8.15.4. STRATEGIC INITIATIVES
8.16. VALENT PHARMACEUTICAL INC.
8.16.1. COMPANY OVERVIEW
8.16.2. PRODUCT PORTFOLIO
8.16.3. SWOT ANALYSIS

TABLE LIST
TABLE 1 NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)
TABLE 2 RECENT MERGERS AND ACQUISITIONS IN ATOPIC DERMATITIS DRUGS MARKET
TABLE 3 NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET BY ROA 2019-2027 ($ MILLION)
TABLE 4 NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET IN TOPICAL ROA 2019-2027 ($ MILLION)
TABLE 5 NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET IN ORAL ROA 2019-2027 ($ MILLION)
TABLE 6 NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET IN INJECTIBLES ROA 2019-2027 ($ MILLION)
TABLE 7 NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET BY DRUG CLASS 2019-2027 ($ MILLION)
TABLE 8 NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET IN TOPICAL ANTIBIOTICS 2019-2027 ($ MILLION)
TABLE 9 NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET IN TOPICAL ANTIHISTAMINES 2019-2027 ($ MILLION)
TABLE 10 NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET IN TOPICAL CORTICOSTEROIDS 2019-2027 ($ MILLION)
TABLE 11 NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET IN TOPICAL MOISTURIZERS/EMOLLIENTS 2019-2027 ($ MILLION)
TABLE 12 NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET IN TOPICAL CALCINEURIN INHIBITORS 2019-2027 ($ MILLION)
TABLE 13 NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET IN IMMUNOMODULATORS 2019-2027 ($ MILLION)
TABLE 14 NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET IN OFF-LABEL THERAPIES 2019-2027 ($ MILLION)
TABLE 15 NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET IN SYSTEMIC AGENTS 2019-2027 ($ MILLION)
TABLE 16 NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET IN PDE4 INHIBITOR 2019-2027 ($ MILLION)
TABLE 17 NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET IN INTERLEUKIN INHIBITOR 2019-2027 ($ MILLION)
TABLE 18 PIPELINE PORTFOLIO OF DIABETES DRUGS MARKET
TABLE 19 REGULATORY FRAMEWORK IN ATOPIC DERMATITIS MARKET
TABLE 20 NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)

FIGURES LIST
FIGURE 1 NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 2 THE UNITED STATES ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 3 CANADA ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)